Drugs / Batiraxcept
Batiraxcept
also known as
AVB-S6-500 · Aravive-S6 · AVB-500 · Axl fc fusion protein avb-s6-500 · Ruga-S6 · S6-500c
Protein / enzyme biologic targets AXL, GAS6 via inhibition
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05826015 | Oct 2024 → Jun 2029 | uterine cancer | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT03607955 | Jun 2021 → Aug 2024 | fallopian tube cancer, malignant epithelial tumor of ovary, primary peritoneal carcinoma | Washington University School of Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT04004442 | Feb 2020 → Apr 2022 overdue | urothelial carcinoma | University of Oklahoma | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03639246 | Dec 2018 → Jan 2021 | ovarian cancer | Aravive, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03401528 | Jan → Jun 2018 | — | Aravive, Inc. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04983407 | Jul 2021 → Aug 2023 | pancreatic adenocarcinoma | Aravive, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04300140 | Feb 2021 → Aug 2023 | clear cell renal carcinoma | Aravive, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04019288 | Dec 2019 → Oct 2024 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04042623 | Nov 2019 → Aug 2020 | IgA glomerulonephritis | Aravive, Inc. | Terminated | No outcome recorded Stop: Business |
| Phase 31 trial | ||||||
| Phase 3 | NCT04729608 | Apr 2021 → Aug 2023 | — | Aravive, Inc. | Terminated | No outcome recorded |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Batiraxcept | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04983407 ↗ |
| Known as | Aravive-S6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594462 ↗ |
| Known as | AVB-500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594462 ↗ |
| Known as | AVB-S6-500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04042623 ↗ |
| Known as | Axl fc fusion protein avb-s6-500 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594462 ↗ |
| Known as | Ruga-S6 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594462 ↗ |
| Known as | S6-500c | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594462 ↗ |
| Action | Inhibit | “AVB-S6-500 is a potent AXL inhibitor by binding to the ligand Gas6” NCT03607955 ↗ |
| Modality | Protein / enzyme biologic | “AXL Fc Fusion Protein AVB-S6-500” NCT04019288 ↗ |
| Route | Intravenous | “Intravenous AVB-S6-500” NCT03401528 ↗ |
| Target | AXL | “Anti-AXL Fusion Protein AVB-S6-500” NCT04019288 ↗ |